Johnson & Johnson shares gain 42% over the past year as talc litigation settles and newer medicines offset weaker revenue

Johnson & Johnson’s stock has climbed sharply over the past year, rising about 42% as investors weighed two opposing forces: progress on longstanding ovarian talc litigation and uneven performance across parts of its medicines portfolio.

In the past year, the company’s shares benefited from expectations around how quickly legal uncertainty could fade. The stock move also tracked the business narrative that Johnson & Johnson has been able to “settle” its ovarian talc claims, reducing a major source of overhang for investors, the latest market write-up said.

At the same time, the rally has been tempered by product-cycle realities. The same account highlighted that Johnson & Johnson’s newer drugs were strong enough to make up for a decline at Stelara, a key medicine where revenue trends have softened. The implication for investors is that growth in newer launches can partially offset declines in mature products, even if the overall mix is not fully smooth.

The stock performance therefore looks less like a single-catalyst story and more like an accumulation of small balance-sheet and pipeline checkpoints. When legal risk appears to narrow and the company can demonstrate momentum in newer therapeutic areas, investors are generally more willing to pay for future cash flows, according to the market framework reflected in the commentary.

Johnson & Johnson’s approach also fits a broader healthcare sector pattern, where large diversified drugmakers face the dual challenge of absorbing expirations, competitive pressure, and patent timelines while continuing to replenish their pipelines. For investors, that balancing act is often measured through how well “new growth” replaces “mature weakness.”

Still, there were gaps in what the post itself disclosed. It did not provide specific settlement timing details, amounts, or any formal guidance updates, nor did it list which “newer drugs” drove the offset against Stelara’s decline. It also did not break out how much of the share price rise could be attributed to litigation developments versus operating performance or market multiple changes.

What to watch next is whether Johnson & Johnson continues to sustain the offset narrative as more detailed financial results land in coming quarters. Investors will likely look for evidence that new product revenue growth is broadening beyond early contributors and that any remaining legal or commercial uncertainties do not re-accelerate.